Trial Profile
A Phase I study of Inotuzumab Ozogamicin as a single agent for pediatric patients in Japan with relapsed/refractory CD22-positive Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Oct 2022
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 01 Oct 2022 Results published in the International Journal of Hematology
- 12 Jul 2021 Status changed from active, no longer recruiting to completed.
- 24 Mar 2020 Status changed from recruiting to active, no longer recruiting.